Using a peptide to disrupt the interaction between GluN2B and MAGUK proteins, the localization of GluN2B-containing NMDAR is altered and allows modulating the dyskinetic motor behavior in an animal model of dyskinesia [181]. This evidence concerns the gene GRIN2B and drug-induced dyskinesia.